Background: The effect of vitamin D replacement on hemoglobin (Hb) concentration in subjects with concurrent deficiencies of vitamin D and iron is not known. Methods: We report on an investigator-initiated, randomized, single-blinded, placebo-controlled, 12-week interventional trial. Thirty subjects with iron-deficiency anemia (serum ferritin <15 µg/l) were randomized to an intervention arm (cholecalciferol, i.e. vitamin D3, 0.6 million units i.m. once) or placebo. In all subjects, iron deficiency was corrected with parental iron. Other causes of anemia were excluded with appropriate investigation. The primary end point was a rise in Hb concentration. Results: Baseline parameters of age, BMI, hemogram values and levels of serum ferritin, 25-hydroxyvitamin D [25(OH)D] and parathyroid hormone (PTH) were similar in the 2 arms. Twelve weeks after vitamin D replacement, there was a significant increase in 25 (OH)D levels (57.7 ± 20.5 vs. 14.1 ± 6.2 ng/ml, p < 0.0001) and a decrease in PTH levels (32.4 ± 16.4 vs. 52.9 ± 18.4 pg/ml, p = 0.003) in subjects in the intervention arm when compared to the placebo arm. However, the increments in serum ferritin and Hb concentration in the intervention and placebo arm did not differ. Conclusion: Vitamin D replacement in subjects with iron-deficiency anemia after iron correction does not improve Hb concentration further.

1.
Ministry of Health and Family Welfare, Government of India. International Institute of Population Sciences and ORC Macro International. National Family Health Survey - 3 (2005-2006). Chapter 10: Nutrition and anemia pp 220-313 (last accessed on July 11, 2012). http://www.aidsdatahub.org/dmdocuments/National_Family_Health_Survey3_2005_06_India_Report_Volume_I.pdf.
2.
Harinarayan CV, Ramalakshmi T, Venkataprasad U: High prevalence of low dietary calcium and low vitamin D status in healthy south Indians. Asia Pac J Clin Nut 2004;13:359-364.
3.
Harinarayan CV: Prevalence of vitamin D insufficiency in postmenopausal south Indian women. Osteoporos Int 2005;16:397-402.
4.
Arya V, Bhambri R, Godbole MM, Mithal A: Vitamin D status and its relationship with bone mineral density in healthy Asian Indians. Osteoporos Int 2004;15:56-61.
5.
Ramakrishnan S, Bhansali A, Bhadada SK, Sharma R, Walia R, Ravikiran M, Shanmugasundar G, Ravikumar P: Vitamin D status and its seasonal variability in healthy young adults in an Asian Indian urban population. Endocr Pract 2011;17:185-191.
6.
Grindulis H, Scott PH, Belton NR, Wharton BA: Combined deficiency of iron and vitamin D in Asian toddlers. Arch Dis Child 1986;61:843-848.
7.
Pike JW: Vitamin D3 receptors: structure and function in transcription. Annu Rev Nutr 1991;11:189-216.
8.
Alon DB, Chaimovitz C, Dvilansky A, Lugassy G, Douvdevani A, Shany S, Nathan I: Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol 2002;30:403-409.
9.
Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, Wolf M: Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010;77:715-720.
10.
Kumar VA, Kujubu DA, Sim JJ, Rasgon SA, Yang PS: Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nnephrol 2011;24:98-105.
11.
WHO. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1986;405:5-37.
12.
Adamson JW: Iron deficiency and other hypoproliferative anemias; in Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (eds): Harrison's Principles of Internal Medicine. New York, McGraw-Hill, 2012, p 849.
13.
Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM, Stallone C: Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo. Nephron Clin Pract 2003;95:c121-c127.
14.
Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-175.
15.
Bhadada SK, Bhansali A, Ahluwalia J, Chanukya GV, Behera A, Dutta P: Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy. Clin Endocrinol (Oxf) 2009;70:527-532.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.